Key points are not available for this paper at this time.
Design
Review
May inform biomarker-guided HF care; leaves open prospective validation in cardiomyopathies.
Cardiovascular diseases are the leading causes of mortality and morbidity in Brazil. The primary and secondary preventions of those diseases are a priority for the health system and require multiple approaches to increase their effectiveness. Biomarkers are tools used to more accurately identify high-risk individuals, to speed the diagnosis, and to aid in treatment and prognosis determination. This review aims to highlight the importance of biomarkers in clinical cardiology practice, and to raise relevant points of their use and the promises for the coming years. This document was divided into two parts, and this first one discusses the use of biomarkers in specific cardiomyopathies and heart failure.
No takes yet. Share an insight, caveat, or question.
A 2014 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: